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Running title: Distinct patterns of C. difficile spread 
 
Summary: Whole-genome sequencing C. difficile across Europe demonstrates two distinct patterns of 
transmission. Healthcare-associated ribotypes showed genetic clustering by country and region, and 
widespread fluoroquinolone resistance. However, multiple common ribotypes showed no within-country 
clustering, consistent with Europe-wide dissemination via non-healthcare routes/sources. 
Abstract 
Background 
Rates of Clostridium difficile infection vary widely across Europe, as do prevalent ribotypes. The extent of 
Europe-wide diversity within each ribotype is however unknown. 
 
Methods 
Inpatient diarrhoeal faecal samples submitted on one day in summer and winter (2012-2013) to laboratories 
in 482 European hospitals were cultured for C. difficile, and isolates ribotyped; those from the 10 most 
prevalent ribotypes were Illumina whole-genome sequenced. Pairwise single nucleotide differences (SNPs) 
were obtained from recombination-corrected maximum-likelihood phylogenies. Within each ribotype, 
country-based sequence clustering was assessed using the ratio of the median SNPs between isolates within 
versus across different countries using permutation tests. Time-scaled Bayesian phylogenies where used to 
reconstruct the historic location of each lineage. 
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Results 
Sequenced isolates (n=624) were from 19 countries. Five ribotypes had within-country clustering: ribotype-
356, only in Italy; ribotype-018, predominantly in Italy; ribotype-176, with distinct Czech and German clades; 
ribotype-001/072, including distinct German, Slovakian, and Spanish clades; and ribotype-027, with multiple 
predominantly country-specific clades including in Hungary, Italy, Germany, Romania and Poland. By 
contrast, we found no within-country clustering for ribotypes 078, 015, 002, 014, and 020, consistent with a 
Europe-wide distribution. Fluoroquinolone-resistance was significantly more common in within-country 
clustered ribotypes (p=0.009). Fluoroquinolone-resistant isolates were also more tightly geographically 
clustered, median (IQR) 43 (0-213) miles between each isolate and the most closely genetically-related 
isolate vs. 421 (204-680) in non-resistant pairs (p<0.001).  
 
Conclusions 
Two distinct patterns of C. difficile ribotype spread were observed, consistent with either predominantly 
healthcare-associated acquisition or Europe-wide dissemination via other routes/sources, e.g. the food 
chain. 
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Background 
Clostridium difficile can spread readily in healthcare facilities,1 and has caused large-scale healthcare-
associated epidemics in the 1990s2 and 2000s,3 particularly with the ribotype-027/NAP1 strain.4 However, 
with enhanced hospital infection prevention and control,5 <40% of cases are estimated to be acquired from 
other symptomatic cases, using whole-genome sequencing in Oxford (35%),6 Leeds (35%),7 Liverpool (37% of 
ribotype-027 cases)8 and six hospitals in England (≤31%),9 and using multi-locus variable number tandem 
repeat analysis in Pennsylvania, USA (30%).10 Antimicrobial restriction has also likely played a key role in 
reducing C. difficile infection (CDI).11 For example, CDIs with clindamycin-resistant12,13 and fluoroquinolone-
resistant14 strains declined in the USA and UK, respectively, following altered antibiotic prescribing. 
 
C. difficile is likely also acquired from other sources, including patients colonised with toxigenic C. difficile 
with diarrhoea of another cause15 or asymptomatic patients,10,16-18 asymptomatically colonised children,19,20 
domestic and production animals, and the food chain.21 C. difficile strains may have particular ecological 
niches, and transmit preferentially in different environments. For example, ribotype-027/NAP1 has 
successfully spread in healthcare settings worldwide.4 Ribotype-001/NAP2 is also found predominantly in 
hospitals, for example in the UK22 and Canada.23 Ribotype-018 was highly transmissible in an Italian hospital 
study,24 and the closely-related ribotype-356 was the most common strain in a survey of Italian hospitals.25 
In the USA, ribotype-027/NAP1 is found in healthcare- and community-associated CDI, but still has the 
greatest ratio of healthcare-associated to community-associated cases amongst the commonly circulating 
strains.26  
 
Other strains have non-healthcare reservoirs, e.g. ribotype-078 has been found in pigs and cattle21,27 with 
close genetic relatedness on whole-genome sequencing between isolates from pigs, healthy farmers and CDI 
cases in the Netherlands.27 Ribotype-078 infections are more likely to be community-acquired and affect 
younger patients.28 In the USA in 2011, ribotype-078/NAP7, ribotype-002/NAP6, and to a lesser extent 
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ribotype-020/014/NAP4, occurred predominantly in community-associated cases based on surveillance 
definitions.26 Community-associated ribotype strains may be widely distributed in the environment; for 
example, ribotype-014, -015, and -078 were all identified at Swiss waste-water treatment plants.29  
 
A recent point-prevalence survey (EUCLID) demonstrated marked Europe-wide variation in both CDI and 
testing rates,30 and prevalent ribotypes.31 We determined the extent of Europe-wide diversity within the ten 
most prevalent ribotypes from that study to investigate whether different modes of transmission could 
plausibly occur across these. We also investigated the relationship between geographic distribution and 
antimicrobial susceptibilities to explore potential drivers of healthcare- and community-associated 
infections.  
 
Methods 
Study design and samples 
Samples were obtained during a European, multicentre, prospective, point-prevalence study of hospital 
inpatients with diarrhoea (EUCLID).30 The study included 20 European countries, each with a national 
coordinating laboratory. National coordinators selected the 482 participating hospitals to cover all major 
geographical regions, at a rate of one per 1 million population. Ethics approval was granted in the 
Netherlands, Sweden, and Slovenia; the remaining countries did not require ethics approval because the 
study was classed as surveillance.  
 
All inpatient diarrhoeal samples submitted to the microbiology laboratory of the participating hospitals on 
two sampling days (one in winter [during December 2012-January 2013], and one in summer [July 2013-
August 2013]) were eligible, irrespective of the original test(s) requested.  Samples from all patients >2 years 
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old currently occupying a hospital bed, including patients in the emergency department, but excluding 
outpatient clinic attendances were included. Only one sample per patient on each sampling day was 
included. All samples were tested for CDI at the national coordinating laboratory using the same 
standardised method, C DIFF QUIK CHEK COMPLETE (Techlab, Orlando, FL, USA); those that were glutamate 
dehydrogenase (GDH) or toxin A/B enzyme immunoassay (EIA) positive were also cultured and isolates sent 
to Leeds General Infirmary microbiology laboratory, UK, for PCR ribotyping.32 7297 inpatient diarrhoeal 
samples were tested at 482 European hospitals,30 resulting in 1211 isolates sent for ribotyping, with 
distribution and characteristics (e.g. age) as described previously.31 
 
Sequencing 
Isolates from the 10 most prevalent toxigenic ribotypes underwent whole-genome sequencing. DNA was 
extracted from subculture of a single colony and sequenced using Illumina HiSeq2500. Sequence data were 
processed as previously,6,33 mapping reads to the C. difficile 630 reference genome (AM180355.1), except 
ribotype-027 and ribotype-078 isolates whose reads were mapped to CD196 (NC_013315.1) and M120 
(FN665653.1) respectively. Sequences were compared using single nucleotide polymorphisms, SNPs, 
obtaining differences between sequences from maximum likelihood phylogenies corrected for 
recombination.34 BEAST v.2.4.335 and BASTA v.2.3.036 were used to reconstruct time-scaled phylogenies, and 
to infer the geographic location of each ancestral lineage. A strength of this approach is that it is possible to 
reconstruct past geographic locations and patterns of geographic spread for each lineage, despite only 
sequencing isolates at two time points. Antimicrobial resistance determinants for fluoroquinolones, 
tetracycline, clindamycin/macrolides, aminoglycosides, and fidaxomicin were identified from mapped data 
and de novo assemblies. Further details are provided in supplementary methods and Table S1. Sequencing 
quality metrics are provided in Table S2. Sequence data generated are available from the NCBI Sequence 
Read Archive under BioProject PRJNA398458 (see Table S3 for study sample metadata). 
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Country-based clustering  
For each ribotype, the median SNPs between isolates within a country (SNPwithin), between sequences across 
different countries (SNPacross), and overall were calculated. Country-based sequence clustering was assessed 
using the SNPwithin:SNPacross ratio; values closer to 0 indicate greater country-based clustering. To determine 
whether observed SNPwithin:SNPacross ratios were compatible with the null hypothesis of no country-based 
clustering, for each ribotype, the country labels of each tip of the phylogenetic tree were permuted 1000 
times. For each permutation, the ratio was calculated. Country-based clustering was supported if the 
observed ratio was less than the 2.5% quantile of the distribution of permuted ratios. As both the overall 
diversity within each ribotype and the number of samples varied, SNPwithin:SNPacross ratios are not directly 
comparable between ribotypes. A similar approach was used to determine, by ribotype, if there was 
evidence of within-hospital clustering in sequences obtained from the same country. 
 
Results 
Of 1211 isolates obtained from 482 European hospitals in 2012-2013, 678 were from the 10 most prevalent 
ribotypes (Figure 1). Of these, 624 (92%) were retrieved and successfully whole-genome sequenced from 
ribotypes 027 (n=216), 001/072 (n=119), 014 (n=80), 002 (n=44), 018 (n=34), 020 (n=33), 078 (n=31), 015 
(n=29), 176 (n=21), 356 (n=17) (Table 1). Sequenced isolates came from 19 countries: Germany (n=268), Italy 
(n=72), Poland (n=56), Hungary (n=46), Romania (n=36), France (n=30), UK (n=29), Czech Republic (n=20), 
Slovakia (n=12), Portugal, Spain, Bulgaria, Belgium, Sweden, Ireland, Netherlands, Austria, Finland, and 
Greece (all n=1-10, see Table 2 for per-country CDI testing-rate/incidence). 
 
Ribotype diversity within and between countries 
Within ribotypes, the overall median SNPs ranged from 9 to 298 (Table 1). Using time-scaled phylogenies, 
the most recent common ancestor for most ribotypes was estimated to date from the 18th to mid-20th 
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century, with the exception of ribotypes 176 and 356 that emerged more recently, in 1993 (95% highest 
posterior density interval, HPD, 1977-2004) and 2008 (2004-2011), respectively. The latter recently evolved 
from ribotype-018 in Italy (Figure S1). 
 
Five ribotypes had evidence of clear within-country clustering: ribotype-356, only found in Italy; ribotype-
018, predominantly isolated in Italy; ribotype-176, with distinct Czech and German clades; ribotype-001/072 
including distinct German, Slovakian, and Spanish clades; and ribotype-027, with multiple predominantly 
country-specific clades including in Hungary, Italy, Germany, Romania and Poland (Figures 2 and S1-3). For 
these ribotypes, the within:between country SNP ratio was significantly lower than expected by chance 
(Table 1), e.g. for ribotype-027 the ratio was 0.60 versus an expected value 0.93-1.07 without any country-
based clustering (95% confidence interval from permutation test).  
 
By contrast, there was no evidence of within-country clustering for ribotypes 078, 015, 002, 014 and 020 
(Figures 3 and S4-7), consistent with recent Europe-wide distribution. For these ribotypes, the 
within:between country SNP ratio was ~1, and fell within the 95% confidence interval expected by chance 
assuming no country-based clustering (Table 1). 
 
For most ribotypes the median (IQR) SNPs between sequences from the same hospital were less than the 
median SNPs within countries, e.g. ribotype-027, 8 (3-26) SNPs compared to 49 (17-71) (Table 3), compatible 
with onward transmission within institutions. For ribotypes showing within-country clustering, based on 
permutation tests, there was evidence of smaller scale within-institution clustering for ribotype-027, 
ribotype-001/072 and ribotype-018. There was limited local and national diversity within ribotype-176 and 
ribotype-356. Amongst ribotypes compatible with a recent pan-European distribution, ribotypes-014, -002 
and -015 had lower within-hospital than within-country median SNPs, but ribotype-020 and ribotype-078 did 
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not. The median SNPs within countries for pairs of sequences not from the same hospital was very similar to 
the median SNPs within countries overall, demonstrating that, where observed, country-based clustering is 
not just driven by hospital-based clustering. 
 
Country-based clustering and antimicrobial resistance 
There was a strong association between within-country clustering and the presence of fluoroquinolone 
resistance determinants (Figure 4). The proportion of isolates with fluoroquinolone resistance was 
significantly higher in the five ribotypes showing within-country clustering, versus the remaining five 
ribotypes (ranksum p=0.009). There was no association between clustering and resistance-determinants for 
three antimicrobials, tetracyclines (p=0.75), aminogylcosides (p=0.41) and clindamycin/macrolides (p=0.22). 
No isolates had previously described fidaxomicin resistance determinants. 
 
All assessable isolates from ribotype-027, -176 and -356 had fluoroquinolone resistance mutations. Only a 
subset of ribotype-018 and -001/072 isolates had resistance mutations allowing the date of the most recent 
common ancestor of each resistant clade to be estimated. In ribotype-018, fluoroquinolone resistance was 
estimated to have emerged in 2001 (95%HPD 1993-2008), followed by a clonal expansion restricted to Italy, 
from which ribotype-356 descended (Figure S1). In ribotype-001/072 fluoroquinolone resistance was 
strongly associated with the presence of ermB conferring resistance to clindamycin and macrolides. Country-
specific clonal expansions of fluoroquinolone/clindamycin/macrolide-resistant ribotype-001/072 strains 
occurred in Germany from 2000 (95%HPD 1992 – 2007), Slovakia from 2006 (2001 – 2010), and Spain from 
1994 (1981 – 2006) (Figure S2).  
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Geographic distance and genetic clustering 
Ribotypes that clustered by country also showed evidence of tighter geographic clustering by region (Figure 
5, Table 1). The median (IQR) geographic distance between each isolate and the next most closely 
genetically-related isolate (using minimum spanning trees to avoid double counting, see Figure 5 legend) 
was 43 (0-213) miles in fluoroquinolone-resistant pairs versus 421 (204-680) miles in non-resistant pairs 
(ranksum p<0.001). By ribotype, the geographic distance between the most closely genetically-related 
isolates was lower for fluoroquinolone-resistant pairs: 21 (0-189), 36 (0-198) and 133 (57-248) miles in 
fluoroquinolone-resistant ribotypes 027, 176 and 356 respectively. In ribotype-001/072, the distance was 56 
(0-221) versus 512 (230-706) miles in fluoroquinolone-resistant versus non-resistant pairs respectively 
(p<0.001), and in-ribotype 018, 160 (53-445) versus 642 (461-750) miles respectively (p=0.08).  
 
By contrast, distances to the most genetically-related isolates in ribotypes without country-based clustering 
were larger, at 443 (191-817), 347 (198-608), 280 (176-564), 542 (256-796), 424 (266-812) miles in 
ribotypes-002, -014, -015, -020 and -078 respectively. 
 
Discussion 
Here we show two distinct patterns of C. difficile ribotype spread. Ribotypes previously associated with 
healthcare-based transmission, including ribotype-027 and ribotype-001/072, demonstrated evidence of 
country, regional, and within-hospital clustering. This geographic structure was preserved over several years 
of C. difficile evolution in each ribotype. In many instances the most plausible source of all cases of a 
particular ribotype, or sub-clade of a ribotype, in a country could be explained by a single imported case, 
suggesting that inter-country transmission of C. difficile with these ribotypes is unusual.  
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By contrast, other ribotypes (002, 014, 015, 020, and 078) showed no evidence of country-based clustering, 
and in many cases the most closely genetically-related strains were separated by several hundred miles. This 
suggests these ribotypes are widely disseminated across Europe, and sustained local transmission is less 
common than the healthcare-associated ribotypes above. It is likely there is still some secondary 
transmission of these ribotypes within hospitals. Although by only sampling on two days six months apart 
the extent of local transmission is not fully captured by this study, we did find evidence of within-hospital 
clustering in in ribotypes 014, 002 and 015. However, the overall pattern observed is consistent with a 
dominant route of spread other than healthcare. The association of ribotype-07827 and ribotype-01437 with 
pig farming, and previous findings of C. difficile in food, raises the possibility that the food chain may be an 
important vector for these ribotypes. The most recent ancestor of pairs of closely related samples from 
these ribotypes was often 5-10 years ago. Therefore, the spread of these strains across Europe may have 
occurred several years previously with persistence in local reservoirs; alternatively, more recent spread may 
have occurred from a reservoir supporting a more diverse C. difficile population than that found in a single 
human host.  
 
We also found that country-based clustering, and therefore likely healthcare-associated transmission, of C. 
difficile was strongly associated with fluoroquinolone resistance, not just in ribotype-027 but also in 
ribotypes-001/072, 018/356 and 176. In ribotype-001/072, fluoroquinolone resistance was found together 
with ermB conferring resistance to clindamycin and macrolides, possibly reflecting fluoroquinolone 
resistance acquisition by an already successfully healthcare-adapted clindamycin-resistant clone; otherwise, 
there was no evidence of associations between country-based clustering and resistance to other 
antimicrobials, including tetracycline and aminoglycosides. We found no evidence of fidaxomicin resistance. 
C. difficile is widely resistant to cephalosporins; therefore, although these can be a risk factor for some 
infections, their use is unlikely to differentially affect the transmission of some ribotypes. Supporting the 
importance of fluoroquinolone use as a driver of healthcare-associated CDI, we recently demonstrated that 
declining CDI incidence in England this millennium can be accounted for by falls in fluoroquinolone-resistant 
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C. difficile, while levels of fluoroquinolone-susceptible C. difficile have remained largely unchanged.14  Clonal 
expansions, representing rapid successful transmission, followed the acquisition of fluoroquinolone 
resistance in two ribotype-027 lineages.4 Here we provide additional examples of clonal expansions 
following acquisition of fluoroquinolone resistance in ribotypes-018 and -001/072 dating from the 1990s 
onwards, consistent with the launch of fluoroquinolones in Europe in 1987.  
 
In contrast to previous findings of He et al,4 who reported frequent and extensive long-range geographic 
transmission within the UK of ribotype-027, transmission events between European countries were 
relatively rare. These typically involved geographically adjacent countries, although we observed probable 
spread from the UK to Poland as well, possibly reflecting the population flows between these countries. We 
were able to observe marked European country-based clustering of some ribotypes because a sufficiently 
large number of isolates were obtained from each country in our study.  
 
A study strength is its unbiased sampling of C. difficile across Europe, with samples obtained on a single day 
in summer and winter, and the number of hospitals from each country based on its population. However, as 
only two single time-points were captured, analyses will tend to under-estimate the extent of local 
secondary transmission for all ribotypes, since this results in genetically-related cases that typically occur 
close in time, but that are not often sampled on the same day.  
 
Other study limitations include the dependence on the rate of submission of diarrhoeal samples to hospital 
laboratories. Despite trying to account for some under-reporting by testing all samples, irrespective of the 
original test requested, patient testing rates varied widely between countries (Table 2). This may have 
impacted the relative prevalence of different ribotypes, but our conclusions regarding within-country 
clustering should be robust to this. In addition, the reconstruction of the ancestral country for each lineage is 
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only an approximation as, due to limited sample size, we had to assume the same effective bacterial 
population size in each country, and the same rates of exchange of strains between all countries. The study 
is also limited by only considering transmission between countries as discrete entities. The study was 
insufficiently powered to explore regional transmission, including the impact of referral networks, hospital 
characteristics and differing patient catchments. These could be investigated in larger national studies, as 
has been done for other healthcare associated pathogens, e.g. methicillin-resistant Staphylococcus aureus.38  
 
Our findings have important implications for C. difficile surveillance and control. C. difficile transmission may 
be more heterogeneous than is usually assumed, with different interventions required for predominantly 
healthcare-associated and community-associated lineages. Surveillance programmes may need to consider 
routine use of typing to allow the incidence of commonly healthcare-associated strains to be followed 
independently of community-associated strains. Although this is theoretically possible with surveillance 
definitions based on the timing of the last healthcare exposure, recent healthcare exposure may merely be a 
marker of exposure to a precipitant of symptoms, e.g. antibiotics, rather than the location of C. difficile 
acquisition.  
 
Measures to control healthcare-associated C. difficile are well-established. However, it is less clear how to 
control the spread of ribotypes that are widely distributed across Europe. Further studies are required to 
better understand potential vectors for transmission, e.g. contaminated food, or use of animal-based 
fertilisers. In principal, better antimicrobial stewardship should reduce the risk of all types of CDI, by 
reducing patients’ exposure to provocative antibiotics. However, as C. difficile antimicrobial resistance is 
associated with country-based clustering, stewardship may have a greater effect on healthcare-associated 
strains. If the non-clustered ribotypes are found very widely in the environment, prevention of exposure 
may be particularly challenging, and other strategies in addition to antimicrobial stewardship may need to 
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be explored to reduce infections, including vaccination or prophylaxis during at risk periods, e.g. around 
healthcare exposures. 
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Figure Legends 
 
Figure 1. Distribution of isolates from sequenced ribotypes by country. Study hospitals were recruited at a 
rate of one per million head of population, hence differences in total isolates obtained between countries 
represent differences in within country testing rates and CDI incidence (see Table 2). 
 
Figure 2. Ribotype-027 phylogeny with ancestral country reconstruction and antimicrobial resistance 
determinants. A time-scaled phylogeny, dated in years, is shown with the branches coloured by the inferred 
country that the ancestral strains were present in over time. The thickness of the lines indicates the level of 
posterior support for the assigned countries; where the posterior support is <0.8 a numeric value is 
provided. Note, the choice of inferred ancestor is limited to those sampled; see Figure 6 for a global 
reconstruction of the deep branches of this phylogeny. The right-hand panel shows for each strain the 
presence of determinants of tetracycline (tetM, tetO, tetB(P), tet0/32/0, tet40, tetA(P)), clindamycin and 
macrolide (ermB), aminoglycoside (aphA1, AAC(6’)-APH(2’)) and fluoroquinolone (gyrA and gyrB mutations) 
resistance. Where de novo assemblies or base calls were not of sufficient quality to make reliable 
assignations the result is denoted Unknown. 
 
Figure 3. Ribotype-078 phylogeny with ancestral country reconstruction and antimicrobial resistance 
determinants. A time-scaled phylogeny, dated in years, is shown with the branches coloured by the inferred 
country that the ancestral strains were present in over time. The thickness of the lines indicates the level of 
posterior support for the assigned countries; where the posterior support is <0.8 a numeric value is 
provided. 
Figure 4. Relationship between ribotypes and presence of resistance determinants. 
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Figure 5. Geographic distance to genetically closest isolate, by ribotype and fluoroquinolone resistance. 
Within each ribotype, a minimum spanning tree was constructed using genetic distances measured in SNPs 
as edge weights and isolates as nodes. The properties of the edges of the minimum-spanning tree are 
plotted, such that every isolate but one contributes one data point. Fluoroquinolone resistant pairs of 
isolates were both fluoroquinolone resistant, and non-fluoroquinolone resistant pairs were either both or 
only one susceptible. One pair of ribotype-014 isolates were both fluoroquinolone resistant, as were two 
pairs of ribotype-078 isolates; however these are insufficient to estimate a kernel density to plot.  
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Tables 
Ribotype Isolates Sequenced 
(% 
sequenced) 
Countries 
found in 
Overall 
median 
(IQR) 
SNPs 
TMRCA  
(95% HPD) 
Within 
country 
median 
(IQR) 
SNPs 
Between 
country 
median 
(IQR) SNPs 
Within: 
between 
country 
SNP ratio 
Expected ratio, 
95% confidence 
interval (from 
permutation)  
Compatible 
with random 
European 
distribution 
Miles 
between 
hospital of 
isolation for 
most closely 
related 
isolates 
(median, 
IQR) 
020 37 33  
(89%) 
9 43  
(34-64)  
1955  
(1920-1986) 
52  
(34-104) 
42  
(34-60) 
1.25 0.84-1.24 Yes 542  
(256-796) 
014 86 80 
(93%) 
13 146  
(66-172) 
1963  
(1924-1995) 
147  
(59-173) 
146  
(68-171) 
1.01 0.87-1.09 Yes 347  
(198-608) 
002 48 44 
(92%) 
11 73  
(61-97) 
1955  
(1922-1986) 
69  
(59-88) 
75  
(62-100) 
0.92 0.88-1.05 Yes 443  
(191-817) 
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015 30 29 
(97%) 
7 298  
(54-366) 
1857  
(1757-1943) 
296  
(29-364) 
346  
(189-433) 
0.86 0.84-1.18 Yes 280  
(176-574) 
078 37 31 
(84%) 
9 54  
(34-148) 
1721  
(1556-1872) 
56  
(29-129) 
54  
(35-152) 
1.04 0.74-1.43 Yes 424  
(266-812) 
027 223 216 
(97%) 
10 71  
(50-110) 
1949  
(1913-1977) 
49  
(17-71) 
82  
(60-125) 
0.60 0.93-1.07 No 21  
(0-189) 
001/072 134 119 
(89%) 
14  201  
(41-273) 
1851  
(1754-1934) 
37  
(23-199) 
253  
(173-322) 
0.15 0.70-1.31 No 184  
(0-351) 
176 25 21 
(84%) 
3 15  
(7-19) 
1993  
(1977-2004) 
6  
(4-8) 
19  
(16-20) 
0.31 0.65-1.23 No 36  
(0-198) 
018 36 34 
(94%) 
7 39  
(22-88) 
1787  
(1638-1910) 
28  
(17-38) 
92  
(83-285) 
0.30 0.40-1.56 No 189  
(53-636) 
356 22 17 1 9  2008  9        No 133  
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(77%) (5-12) (2004-2011) (5-12) (57-248) 
 
Table 1. Extent of within-country clustering by ribotype. TMRCA, time of most recent common ancestor; HPD, highest posterior density interval. To 
calculate the number of miles between the most closely related isolates, within each ribotype, a minimum spanning tree was constructed using SNP 
distances as edge weights and isolates as nodes. The properties of the edges (SNPs and miles) of the minimum-spanning tree were analysed, such that each 
isolate, but one, contributes one data point (see Figure 5). 
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy252/4962508
by Medical Library, Seacroft Hospital user
on 20 April 2018
  
 
 Mean measured CDI rate per 
10 000 bed days 
Mean measured testing rate 
per 10 000 bed days 
Austria 7.2 102.0 
Belgium 5.4 95.4 
Bulgaria 32.2 1.0 
Czech Republic 18.9 140.0 
Finland 12.6 102.2 
France 3.8 38.8 
Germany 24.8 137.2 
Greece 3.5 56.4 
Hungary 17.7 71.7 
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Ireland 6.1 274.5 
Italy 11.9 67.7 
Netherlands 6.1 88.1 
Poland 38.9 135.0 
Portugal 17.0 72.3 
Romania 93.4 35.4 
Slovakia 16.9 84.2 
Spain 10.4 95.2 
Sweden 11.9 71.8 
UK 5.7 115.8 
Europe 18.1 93.9 
 
Table 2. Mean measured CDI rate and testing rate per 10 000 bed days. Mean values are given averaging over winter and summer sampling days. 
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Ribotype Within country SNPs Within hospital SNPs Within country, different 
hospital SNPs 
Within:different 
hospitals median 
SNP ratio 
Expected 
ratio, 95% 
confidence 
interval (from 
permutation)  
Compatible with 
hospital-based 
clustering 
 Median IQR Median IQR Median IQR    
020 52 (34-104) 40 (31-105) 54 (35-104) 0.74 (0.51-2.04) No 
014 147 (59-173) 32 (0-137) 148 (60-173) 0.21 (0.42-1.17) Yes 
002 69 (59-88) 3 (0-21) 69 (60-88) 0.05 (0.65-1.36) Yes 
015 296 (29-364) 2 (0-2) 296 (41-365) 0.01 (0.14-1.47) Yes 
078 56 (29-129) 125 (1-250) 56 (32-128) 2.26 (0.15-3.86) No 
027 49 (17-71) 8 (3-26) 50 (19-71) 0.16 (0.42-0.56) Yes 
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001/072 37 (23-199) 9 (4-31) 38 (24-201) 0.23 (0.70-1.09) Yes 
176 6 (4-8) 7 (2-8) 6 (4-8) 1.17 (0.66-1.17) Limited total 
diversity 
018 28 (17-38) 7 (4-11) 29 (17-38) 0.23 (0.52-1.38) Yes 
356 9 (5-12) 7 (0-7) 9 (5-12) 0.78 (0.22-1.56) Limited total 
diversity 
 
Table 3. Extent of within-hospital clustering by ribotype.  
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Figure 1. 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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